Topical Ozenoxacin Cream 1% for Impetigo: A Review

Abstract

Background: Impetigo, a bacterial infection that is highly contagious, involves the superficial skin. Topical treatment for impetigo includes amongst other bacitracin, gentamycin, mupirocin, retapamulin, and more recently, ozenoxacin 1% cream. For more severe conditions systemic antibiotics are prescribed and may be combined with a topical treatment. The current review explored the challenges in treating impetigo in pediatric and adult populations and examined the role of ozenoxacin 1% cream as a safe and effective treatment option. Methods: We performed PubMed and Google Scholar searches of the English-language literature (2010-2018) using the terms impetigo, bullous impetigo, non-bullous impetigo, antimicrobial and antibiotic resistance, mupirocin, retapamulin, and ozenoxacin. The selected publications were manually reviewed for additional resources. Results: Although guidelines were updated regularly, the recommended treatments have not changed much since 2014. Emerging antimicrobial resistance is a growing concern in dermatology and pediatrics. Impetigo therapy choices should consider the resistance pattern of S. aureus. Ozenoxacin 1% cream is a prescription medicine for topical treatment of impetigo in adults and children 2 months or older. Ozenoxacin has a low probability of selecting spontaneous resistant mutants in quinolone-susceptible or quinolone-resistant bacterial strains and has shown to be active against MRSA isolates. Ozenoxacin 1% cream has potent bactericidal activity and was shown to be effective and safe for the treatment of impetigo in two well-controlled Phase 3 trials. Conclusions: Resistance patterns in a wide range of pathogens against oral or topical antibiotics and antiseptics used for the treatment of dermatological conditions, such as impetigo have been observed. When making treatment decisions for impetigo MRSA and other antimicrobial resistance has to be taken into account. Ozenoxacin 1% cream offers a potent bactericidal activity and has demonstrated clinical efficacy and safety. Combined with its favorable features, such as a low dosing frequency and a 5 days treatment regimen, ozenoxacin 1% cream is an important option for the treatment of impetigo for pediatric and adult populations. J Drugs Dermatol. 2019;18(7):655-661.

• Authors: Lawrence Schachner, Anneke Andriessen, Neal Bhatia, Ayman Grada, Dillon Patele
• Journal: Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 18 Issue 7 Pg. 655-661 (Jul 01 2019) ISSN: 1545-9616 [Print] United States
• PMID: 31334625 (Publication Type: Journal Article, Review)

Chemical References

• Aminopyridines
• Anti-Bacterial Agents
• Quinolones
• ozenoxacin

Topics

• Aminopyridines (pharmacology, therapeutic use)
• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Antimicrobial Stewardship (standards)
• Clinical Decision-Making
• Drug Resistance, Bacterial (drug effects, genetics)
• Humans
• Impetigo (drug therapy, microbiology)
• Mutation (drug effects)
• Patient Selection
• Practice Guidelines as Topic
• Quinolones (pharmacology, therapeutic use)
• Skin Cream (administration & dosage)
• Staphylococcus aureus (isolation & purification, physiology)
• Treatment Outcome